Non-Melanoma Skin Cancer following Hydrochlorothiazide Use: A Propensity Score Matched Analysis

Project Title Non-Melanoma Skin Cancer following Hydrochlorothiazide Use: A Propensity Score Matched Analysis
Date Posted
Tuesday, June 11, 2019
Project ID
cder_mpl2p_wp016
Status
In progress
Deliverables
Related Links
Description

This analysis investigates the risk of non-melanoma skin cancer for patients treated with hydrochlorothiazide-containing products compared to non-hydroclorothiazide angiotensin-converting-enzyme inhibitor (ACEI)-containing products, including captopril, enalapril maleate, and lisinopril monotherapies and combination therapies in the Sentinel Distributed Database.

The analytic package associated with this analysis can be found externally in Sentinel's Git Repository located here. The Git Repository serves as Sentinel's version control tracking system for analytic packages and technical documentation.

Medical Product
hydrochlorothiazide (HCTZ)
Health Outcome
non-melanoma skin cancer
Population / Cohort
All individuals
Time Period
January 1, 2000 - February 1, 2019
Assessment Type
Safety Analyses
Study Type
Modular Program
Data Sources
Sentinel Distributed Database (SDD)
FDA Center
CDER